论文部分内容阅读
为探讨慢性粒细胞白血病（ＣＭＬ）的发生及发展机制。对４３例不同疾病阶段的患者进行了细胞遗传学的研究，发现９２％的初治及７３％的治疗后患者存在Ｐｈ染色体，６５％的加速期及急变期患者还伴有附加染色体改变；同时对３７例患者进行了分子生物学的检测，９５％的患者存在ｂｃｒ／ａｂｌ融合基因，其中包括４例Ｐｈ阴性患者，融合基因持续存在于整个病程中，且转录本ｂ２ａ２及ｂ３ａ２同样可见，未发现有ｅ１ａ２。结果表明ＣＭＬ的发生及进展存在着特异性的细胞遗传学及分子生物学基础，ｂｃｒ／ａｂｌ融合基因检测是ＣＭＬ诊断最灵敏且特异的方法，但预后意义不大
To investigate the occurrence and development mechanism of chronic myelogenous leukemia (CML). A cytogenetic study of 43 patients with different disease stages revealed that Ph chromosomes were present in 92% of newly diagnosed patients and 73% of patients after treatment. Additional chromosome changes were also associated with 65% of patients in the accelerated and blast phase. Thirty-seven patients were tested for molecular biology, 95% of patients had bcr/abl fusion gene, including 4 patients with Ph negative, fusion genes persisted throughout the course of the disease, and transcripts b2a2 and b3a2 were also visible. Found that there is e1a2. The results show that there are specific cytogenetic and molecular biological basis for the occurrence and progression of CML. The detection of bcr/abl fusion gene is the most sensitive and specific method for CML diagnosis, but the prognosis is not significant.